Celgene International Sárl Release: Phase II Data Evaluating Clinical Benefit of REVLIMID(R) Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID (lenalidomide) plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin’s lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.